Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years old
Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL;
Sign an informed consent form;
Researchers evaluate patients who can benefit from receiving immunochemotherapy.
You may not be if
There are contraindications to any medication in the treatment plan;
Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication;
Researchers believe that patients who are not suitable for enrollment.
Clareo Health | Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
